中华实验和临床感染病杂志（电子版）
中華實驗和臨床感染病雜誌（電子版）
중화실험화림상감염병잡지（전자판）
CHINESE JOURNAL OF EXPERIMENTAL AND CLINICAL INFECTIOUS DISEASES(ELECTRONIC VERSION)
2013年
4期
584-587
,共4页
慢性丙型肝炎%低剂量%干扰素%个体化治疗%病毒学应答
慢性丙型肝炎%低劑量%榦擾素%箇體化治療%病毒學應答
만성병형간염%저제량%간우소%개체화치료%병독학응답
Chronic hepatitis C%Low-dose%Interferon%Individualized therapy%Virological response
目的：观察不能耐受标准剂量干扰素治疗方案的部分丙型肝炎患者干扰素个体化给药的疗效，探索不同剂量干扰素治疗丙型肝炎的方法。方法收集多种原因不能耐受标准剂量干扰素治疗方案的丙型肝炎患者共28例，给予个体化低剂量干扰素（普通干扰素0.8～3 MIU/d，隔日1次）联合利巴韦林0.6～0.9 g/d治疗，疗程48周。结果89.29%（25/28）患者可耐受低剂量干扰素联合利巴韦林长期治疗。不同时间节点的病毒学应答率为：4周病毒学应答率（RVR）为7.04%，12周病毒学应答率（EVR）为17.85%、24周病毒学应答率53.85%、48周病毒学应答率为60.00%。停药后24周病毒学应答率（SVR）为48.00%。结论抗丙型肝炎病毒治疗可以改善肝功能，从而提高患者对高效抗逆转录病毒治疗的耐受性。
目的：觀察不能耐受標準劑量榦擾素治療方案的部分丙型肝炎患者榦擾素箇體化給藥的療效，探索不同劑量榦擾素治療丙型肝炎的方法。方法收集多種原因不能耐受標準劑量榦擾素治療方案的丙型肝炎患者共28例，給予箇體化低劑量榦擾素（普通榦擾素0.8～3 MIU/d，隔日1次）聯閤利巴韋林0.6～0.9 g/d治療，療程48週。結果89.29%（25/28）患者可耐受低劑量榦擾素聯閤利巴韋林長期治療。不同時間節點的病毒學應答率為：4週病毒學應答率（RVR）為7.04%，12週病毒學應答率（EVR）為17.85%、24週病毒學應答率53.85%、48週病毒學應答率為60.00%。停藥後24週病毒學應答率（SVR）為48.00%。結論抗丙型肝炎病毒治療可以改善肝功能，從而提高患者對高效抗逆轉錄病毒治療的耐受性。
목적：관찰불능내수표준제량간우소치료방안적부분병형간염환자간우소개체화급약적료효，탐색불동제량간우소치료병형간염적방법。방법수집다충원인불능내수표준제량간우소치료방안적병형간염환자공28례，급여개체화저제량간우소（보통간우소0.8～3 MIU/d，격일1차）연합리파위림0.6～0.9 g/d치료，료정48주。결과89.29%（25/28）환자가내수저제량간우소연합리파위림장기치료。불동시간절점적병독학응답솔위：4주병독학응답솔（RVR）위7.04%，12주병독학응답솔（EVR）위17.85%、24주병독학응답솔53.85%、48주병독학응답솔위60.00%。정약후24주병독학응답솔（SVR）위48.00%。결론항병형간염병독치료가이개선간공능，종이제고환자대고효항역전록병독치료적내수성。
Objective To investigate the effect of individualized therapeutic programs with interferon in patients with chronic hepatitis C (CHC) who could’t tolerate the therapy with standard dose of interferon and explore the methods of therapy with different doses of interferon in patients with CHC. Methods Total of 28 cases of patients with CHC who could’t tolerate the therapy with standard dose of interferon received the individual low-dose interferon (ordinary IFN 0.8-3 MIU once every other day) in combination with ribavirin 0.6-0.9 g/d. The course of treatment was 48 weeks. Results There were 89.29%(25/28) patients with CHC could tolerate low-dose interferon in combination with ribavirin in long-term treatment. For patients treated for 4 weeks, the rapid virological response (RVR) rate was 7.04%. For those treated for 12 weeks, the early virological response (EVR) rate was 17.85%. For those treated for 24 weeks, the virological response rate was 53.85%. For those treated for 48 weeks, the virological response rate was 60.00%. All patients were followed-up for 24 weeks after the end of the treatment, and the sustained virological response (SVR) rate was 48.00%. Conclusions Anti-HCV therapy could improve liver function of the patients with HCV infection, consequently, it can improve the tolerability of highly active antiretroviral therapy.
